ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1622079
Immune Function Analysis in a Pediatric Patient with a de novo ALPK1 Gene Mutation
Provisionally accepted- Affiliated Stomatological Hospital of Zunyi Medical University, Zunyi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Introduction: ROSAH syndrome is a rare autosomal dominant disorder caused by heterozygous missense mutations in the ALPK1 gene. It is clinically characterized by a spectrum of manifestations, including retinal dystrophy, optic disc edema, splenomegaly, anhidrosis, and headaches. This study performed an integrated evaluation of clinical manifestations, genetic alterations, and immunological profiles in a pediatric ROSAH syndrome case harboring an ALPK1 mutation, with the objective of dissecting its putative immune-mediated pathogenesis. Methods: A 12-year-old male with unexplained splenomegaly and multisystem symptoms underwent clinical evaluation. Whole-exome and Sanger sequencing were used to identify ALPK1 variants. Western blotting elucidated the ALPK1 protein expression alongside the activation status of the NF-κB pathway in peripheral blood mononuclear cells (PBMCs), coupled with flow cytometric characterization of T-and B-lymphocyte subset distributions. Clinical manifestations and treatment of ROSAH Syndrome caused by ALPK1 mutations were summarized by literature review. Results: The individual presented with progressive visual loss, anhidrosis, migraine, and arthralgia. A heterozygous de novo ALPK1 variant (c.710C>T, p.Thr237Met) was identified. Elevated ALPK1 and phosphorylated IKKβ levels indicated NF-κB pathway activation. Lymphocyte profiling demonstrated markedly diminished CD3+ and CD8+ T-cell counts, with the CD4+/CD8+ ratio escalating to 2.61, concurrently with elevated proportions of activated CD4+, CD8+ T cells, and regulatory T-cell populations. B-cell lineage anomalies featured expansions in transitional B-cell subsets and plasmablasts, paralleled by reduced serum immunoglobulin concentrations. Approximately 70 cases have been reported globally, linked to four ALPK1 mutations (c.710C>T, c.761A>G, c.830C>T, c.476C>T). Key clinical features include severe ocular involvement (retinal degeneration, optic nerve edema) and systemic manifestations such as splenomegaly and anhidrosis. Current management focuses on anti-inflammatory therapy and symptomatic support, while retinal degeneration remains untreatable. Discussion: This case links a de novo ALPK1 mutation to constitutive NF-κB activation and immune dysfunction in ROSAH syndrome. Early genetic and immunological screening is essential for diagnosis and management of ROSAH syndrome. Targeted immunotherapy may alleviate symptoms, but further research is needed to define standardized approaches for this rare disorder.
Keywords: ALPK1, ROSAH syndrome, Immune function, NF-κB pathway, Targeted immunotherapy
Received: 02 May 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 CHUAN, Ren, Li, Zhang, Zhu, Wang, Du, Chen, Huang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zuochen Du, dzc9036@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.